Abstract. Nasopharyngeal carcinoma (NPC) is a prevalent tumor that affects the head and neck. Radiation therapy is typically used to treat NPC; however, poor prognoses and distant metastases are common due to radiation resistance. The anti-tumor activities of trichosanthin (TCS) have been reported in several types of tumors. The aim of the present study was to investigate whether TCS may serve as a potential radiosensitizer in the treatment of NPC tumors. In the present study, NPC cells were treated with radiation alone or together with TCS and radiosensitivity was compared. Clonogenic assay, flow cytometry and an animal study were performed to assess cell death in NPC. The clonogenic assay demonstrated that TCS had a significant radiosensitizing effect on NPC cells. Western blotting indicated that phosphorylated protein kinase B and signal-regulated kinase [phosphoinositide 3-kinase (PI3K) pathway] were downregulated, and that cleaved caspase-3 was upregulated by combined treatment with TCS and radiation. Furthermore, TCS potently radiosensitized NPC xenografts in vivo. In conclusion, TCS radiosensitized NPC in vitro and in vivo via downregulation of PI3K pathways and the upregulation of cleaved caspase-3.

Introduction

Trichosanthin (TCS) is purified from the root tuber of Trichosanthes kirilowii (1). In China, TCS has been used historically as an abortifacient agent in early and midterm pregnancy and to treat invasive moles, ectopic pregnancies and hydatidiform moles (1,2). TCS is a typical type I ribosome-inactivating protein, which attacks eukaryotic cells ribosomes via its rRNA N-glycosidase activities (2). In recent years, the biological and pharmacological activities of TCS have been investigated (1). A previous study has reported that TCS may serve as a potential anticancer agent via suppressing the proliferation of various cancer cell types, including melanoma, colon carcinoma, lung cancer, stomach cancer, breast cancer, hematoma and prostate cancer (3). TCS has been demonstrated to suppress the proliferation of HeLa cells by obstructing the protein kinase C/mitogen activated protein kinase signaling pathway and increasing cytosolic Ca²⁺ concentrations (2,4,5). TCS also successfully reduced human choriocarcinoma cell proliferation by upregulating reactive oxygen species production (4). TCS triggers apoptosis in human lung cancer cells via anti-telomerase effects and inhibiting cell migration and metastasis, as well as inducing G1 phase arrest (5).

Nasopharyngeal carcinoma (NPC) is a prevalent head and neck malignant tumor that arises in the nasopharyngeal epithelium, with annual incidence rate of 54.7 cases per 100,000 individuals in South East Asia, Southeast China, the Middle East, Northeast Africa and Alaska (6-8). The current NPC treatment strategy primarily relies on radiotherapy (9,10). In the 1960s and 1970s, the 5-year survival rate for NPC was 0% (10). In the 2000s, however, this was successfully increased to >80% (10). Although intensity-modulated radiation therapy and concurrent chemo-radiotherapy have proved effective for regional NPC control, the prognoses of patients with distant metastasis remains poor (8). Furthermore, typical radiation doses are ~70 Gy in adults and ~60 Gy in children and adolescents, with the additional application of chemotherapy (6). Such high doses may lead to late toxicities of xerostomia, neck fibrosis, dental caries, trismus, hypopituitarism, stunted growth, hearing loss and secondary malignancies in ~70% of patients (6).

The development of radiation-sensitizing agents may decrease the effective radiation dose in NPC, reducing the incidence of negative side effects. The aim of the present study therefore was to investigate the radiation-sensitizing effects of TCS in NPC and the underlying mechanisms responsible.

Materials and methods

Reagents. TCS (98% purity) was procured from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany) and dissolved in...
dimethylsulfoxide (DMSO) to generate a stock solution. The stock solution was then further diluted with RPMI-1640 complete medium (Thermo Fisher Scientific, Inc., Waltham, MA, USA) to make the final concentration of 0.05%. Antibodies against cleaved caspase-3 were provided by Cell Signaling Technology, Inc. (Danvers, MA, USA; cat. no. 9661). Phosphorylated (p)-protein kinase B (AKT; cat. no. SC101629), p-extracellular signal-regulated kinase (ERK; cat. no. SC136521) and GAPDH (cat. no. SC293335) were obtained from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). The secondary antibodies utilized were horseradish peroxidase (HRP) conjugated rabbit monoclonal antibodies (cat. no. 5571) and HRP conjugated anti-mouse immunoglobulin G (cat. no. 7076), which were both provided by Cell Signaling Technology, Inc.

**Cell culture.** The NPC cell line SUNE-1 was obtained from the Cancer Institute and Hospital, Chinese Academy of Medical Sciences (Beijing, China) and cultured in RPMI-1640 medium containing 5% fetal bovine serum (FBS; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and penicillin and 100 mg/ml streptomycin under standard conditions (37°C and 5% CO₂). Radiation was administrated as a single treatment or combined with TCS. Combination Index (CI) analysis was used to investigate the synergy between two therapies based on the method of Chou et al (11).

**Clonogenic survival assay.** A Gulmay machine (FCS320; Gulmay Incorporated, Shanghai, China) operating with 250 kVp at 0.65 Gy/min X-ray radiation was used. SUNE-1 cells were seeded at a density of 2x10⁵ cells/well and grown in 6-well plates for 5 h (37°C, 5% CO₂). Cells were divided into five groups: DMSO control, 4 Gy irradiation alone, 20 µM TCS alone, 4 Gy irradiation + 10 µM TCS or 4 Gy irradiation + 20 µM TCS. Cells were first treated with DMSO or TCS and subsequently irradiated at room temperature. Following irradiation, cells were further incubated for 24 h for colony formation. Colonies with >50 cells were taken into account to calculate the survival fraction. The linear-quadratic model of Kaleidagraph version 3.51 (Synergy Software, Reading, PA, USA) was used to analyze survival data. Experiments were repeated a minimum of three times and the mean survival fraction was calculated.

**Cell apoptosis assay and flow cytometry.** Cell apoptosis was measured using an Annexin V-fluorescein isothiocyanate (FITC) Apoptosis Detection kit (Sigma-Aldrich; Merck KGaA). SUNE-1 cells were resuspended in PBS, seeded in 6-well plates (1x10⁵ cells/well) and incubated overnight at 37°C to allow them to attach. Cells were treated with TCS or DMSO for 24 h at 37°C, harvested, washed twice with ice-cold PBS and resuspended in 250 µl binding buffer (as provided by the kit). Cells were stained with 5 µl Annexin V-FITC and propidium iodide (PI) in the dark for 30 min at room temperature, following which they were analyzed using a flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA).

**Western blot analysis.** Total cell proteins were extracted for western blot analysis. NPC cells were harvested and lysed in cell lysis buffer (Bio-Rad Laboratories, Inc., Hercules, CA, USA), including complete protease inhibitor cocktail (Roche Diagnostics, Basel, Switzerland) and phosphatase inhibitor cocktail (Sigma-Aldrich; Merck KGaA) for 2 h, followed by centrifugation at a speed of 1,000 x g) for 30 min at 4°C. Protein concentrations were determined using a bicinchoninic acid Protein Assay kit (Pierce; Thermo Fisher Scientific, Inc.). Equal quantities of protein (50 mg) were separated by 10 and 15% SDS-PAGE and transferred onto polyvinylidene difluoride membranes. Polyvinylidene difluoride membranes were blocked in 5% skimmed milk at room temperature for 1 h and incubated sequentially with the primary (1:1,000) and secondary (1:5,000) antibodies (listed in the reagents section) overnight at 4°C. Membranes were washed three times with TBS supplemented with Twee-20 (pH 7.4; 10 mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20) and bands were visualized using a chemiluminescence reagent (EMD Millipore, Billerica, MA, USA) and BioMax™ XAR film (Kodak, Rochester, NY, USA). ImageJ software (version 1.45; National Institutes of Health, Bethesda, MD, USA) was used to analyze band intensities.

**In vivo experiments.** A total of 30 female BALB/c nude mice (7-week old, 20-25 g) were supplied by Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China) and housed under a 12 h light/dark cycle kept at 22°C with a humidity of 60%. Mice received free access to an autoclaved laboratory rodent diet and water. All animal experiments were approved by the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou Animal Research Ethics Committee (Zhengzhou, UK). SUNE-1 human NPC cells were suspended in 100 ml RPMI-1640 medium mixed with 100 ml Matrigel™ Matrix (BD Biosciences). To construct the xenograft tumor model, cells were inoculated subcutaneously into the right flanks of BALB/c nude mice. Once the tumors reached ~200 mm³, the mice were randomly assigned into four groups (n=6 in each). Groups received the following treatment: 50 mg/kg/day TCS via oral gavage (12), 4 Gy irradiation, 4 Gy irradiation + daily 50 mg/kg/day TCS via oral gavage or normal saline via oral gavage for 5 weeks. Tumor volumes were monitored weekly and measured in two dimensions (length and width) with calipers. Tumor volumes were calculated using the following formula: Tumor size=(length x width²)/2. After 5 weeks, mice were sacrificed and tumors were harvested and weighed.

**Statistical analysis.** Data were analyzed using one-way analysis of variance or Student’s t-test with PRISM 5.0 (GraphPad Software Inc., La Jolla, CA, USA). P<0.05 was considered to indicate a statistically significant difference. Data are presented as the mean ± standard deviation.

**Results**

**Combined treatment with TCS and radiation reduced the survival fraction of SUNE-1 cells.** The survival fraction of SUNE-1 cells was calculated to assess the anti-proliferative effects of TCS and radiation. The results demonstrated that SUNE-1 cell growth was markedly inhibited by irradiation alone compared with the control cells (Fig. 1A). In addition, the combination of TCS with radiation inhibited cell growth markedly more than radiation alone (Fig. 1A). No marked survival inhibition was observed with TCS treatment
had no significant effect of the expression of p-ERK and p-AKT in SUNE-1 cells (Fig. 3A). However, compared with the control group, p-ERK and p-AKT were downregulated following exposure to radiation and were further downregulated by combined treatment with TCS and radiation (Fig. 3A). The results of western blotting also indicated that combined treatment with TCS and radiation significantly increased the expression of cleaved caspase-3 compared with radiation alone and the control group (Fig. 3B). Cells treated with 20 µM TCS and radiation therapy had significantly lower p-ERK and p-AKT expression compared with the 10 µM TCS combined treatment group, which was consistent with previous apoptosis analysis and survival fraction analysis results (Fig. 3C and D). These results suggest that TCS was able to radiosensitize SUNE-1 cells via inhibiting the PI3K/AKT signaling pathway.

**TCS in combination with radiation inhibits tumor growth in SUNE-1 xenografts.** In order to further confirm the radiosensitization ability of TCS in vivo, SUNE-1 xenografts were constructed. Consistent with the in vitro results, combined treatment with TCS and radiation inhibited SUNE-1 tumor growth in a xenograft tumor model (Fig. 4A). At the end of week 5, mice were sacrificed and tumors were resected for weighing. Tumor weight was significantly lower in the radiation only and TCS combination with radiation groups compared with the control group (Fig. 4B and C). Changes in body weight were recorded throughout the experimental period and no significant differences were observed between groups (Fig. 4D). In conclusion, radiation therapy alone significantly inhibits NPC tumor growth in mice, whereas combined treatment with TCS and radiation may be more effective.

**Discussion**

Radiotherapy is currently the primary treatment for patients with NPC, however radioresistance results in poor patient prognosis (13,14) and the relapse rate is as high as 82% (15,16). Once relapse or metastases occur, the 5-year survival rate is greatly reduced (16). Low radiosensitivity contributes to the poor overall survival of patients with recurrent NPC (17). Cancer cells exhibit different levels of radiosensitivity due to tumor cell heterogeneity. Even when NPC cells are of the same histological differentiation status, radiosensitivity varies (17). The development of novel therapeutic strategies to overcome radioresistance and enhance the radiosensitivity of NPC are urgently required.

The antitumor effect of TCS has been reported in a number of previous studies. Fang et al (5) reported that TCS inhibits breast cancer cell proliferation and induces apoptosis via the activation of both caspase-8 and caspase-9 regulated pathways. Miao et al (4) reported that TCS successfully induced apoptosis in glioma cells in a dose- and time-dependent manner in vitro, as well as significantly reducing prostate tumor weight and prostate tumor volume in vivo (2). In the present study, it was demonstrated that TCS potentially radiosensitizes...
NPC xenografts in vitro and in vivo via downregulation of the p-AKT and p-ERK signaling pathways. Considering the clinical usage of TCS on other human diseases, these results suggest that TCS may be used as a novel treatment for NPC.

Recombinant TCS has been demonstrated to inhibit prostate cancer by activating the caspase-8-regulatory pathway to induce the apoptosis of PC3 cells (2). Further research is required to explore the antitumor effects of TCS in other tumor types. Furthermore, the mechanism underlying the antitumor effects of TCS has not been fully elucidated. A more systematic and comprehensive analysis of these mechanisms is essential to facilitate the application of TCS as a clinical tumor treatment strategy.

In addition to TCS, other reagents have been reported to radiosensitize NPC cells. Rad51 is a protein that serves a critical role in the repair of DNA double-strand breaks following irradiation. One study reported that the radiosensitivity of NPC cells could be enhanced by the inhibition of autophagy via reducing Rad51 expression (17). As a result, Rad51 may be a potential novel adjuvant treatment reagent for NPC (17).

It has also been reported that curcumin is able to radiosensitize NPC cells both in vivo and in vitro via the upregulation of microRNA (miR)-593 (18). MiR-593 reduces multi-drug resistance gene 1 expression and therefore promotes radiosensitivity in NPC cells (18). According to Liu et al (19), the inhibitors GSK2126458 and PKI-587 represses the progression of four NPC cell lines (SUNE-1, CNE2, 5-8F and 6-10B) and inhibits tumor growth in vitro via the PI3K/mammalian target of rapamycin (mTOR) signaling pathway. NPC cell apoptosis was increased via the suppression of AKT, mTOR and 4EBP1 phosphorylation by GSK2126458 and PKI-587. Furthermore, NPC cells were sensitized to radiation by DNA damage induced by GSK2126458 and PKI-587, which enhanced G2-M cell-cycle delay and induced apoptosis (19).

In conclusion, a number of novel reagents including TCS are able to reduce the radioresistance of NPC cancer cells and may be used in combination with radiotherapy to improve the prognosis of patients with cancer.
Figure 3. TCS radiosensitized SUNE-1 cells via downregulating the phosphoinositide 3-kinase signaling pathway. Cells were treated with 0, 10 or 20 µM TCS and/or exposed to 4 Gy radiation with dimethylsulfoxide as the control. (A) The expression of p-AKT, AKT, p-ERK, ERK and cleaved caspase-3 was assessed using western blotting. GAPDH expression was used as a loading control. (B-D) The semi-quantification of proteins concentrations were tested using with ImageJ software. The results are presented as the mean ± SD of three independent experiments. *P<0.05 and **P<0.01 vs. control. *P<0.05 and ##P<0.01 vs. radiation alone. TCS, trichosanthin; p, phosphorylated; AKT, protein kinase B; ERK, extracellular signal-regulated kinase.

Figure 4. Combined treatment with TCS and radiation inhibited tumor growth in SUNE-1 xenografts. (A) 7-week old BALB/c mice were subcutaneously injected with SUNE-1 cells and treated with vehicle, 50 mg/kg/day TCS, 4 Gy radiation or 50 mg/kg/day TCS + 4 Gy radiation for 5 weeks and tumor volumes were monitored. Scale bar=1 cm. At the end of week 5, mice were sacrificed and tumors were (B) excised and (C) weighed. (D) Mice were weighed weekly throughout the experimental period. *P<0.05 and **P<0.01 vs. control; *P<0.05 vs. radiation. TCS, trichosanthin.
Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

All authors performed the experiments. WW, JW, RQ, XLi, DL and XLiu analyzed the data. WW and JW designed the study, and BT and IZ drafted the manuscript.

Ethics approval and consent to participate

All animal experiments were approved by the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou Animal Research Ethics Committee (Zhengzhou, China).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References